Avalo Director Receives 20,100 Stock Options at $4.47 Strike Price

Insider Trading Alert: Avalo Therapeutics (AVTX) director Gilla Kaplan received a stock option grant on June 17, 2025.

Rhea-AI Filing Summary

Insider Trading Alert: Avalo Therapeutics (AVTX) director Gilla Kaplan received a stock option grant on June 17, 2025. The derivative securities transaction involved 20,100 stock options with the following key terms:

• Exercise price set at $4.47 per share
• Options expire on June 17, 2035
• 100% vesting occurs on the first anniversary of grant date
• Vesting conditional on continued service as director

This Form 4 filing discloses a standard director compensation stock option grant, suggesting continued alignment of director interests with shareholders through equity-based compensation. The filing was signed by Donald R. Reynolds via Power of Attorney on June 18, 2025.

Insider Trade Summary

Grant/Award: 20,100 shares

Grant/Award 1 txn

Insider KAPLAN GILLA

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	20,100	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 20,100 contracts (Direct)

Footnotes (1)

1. F1. The stock option vests 100% on the first anniversary of the date of grant, subject to the Eligible Director's continued service on such vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stock options were granted to AVTX director Gilla Kaplan in June 2025?

Director Gilla Kaplan was granted 20,100 stock options on June 17, 2025, with an exercise price of $4.47 per share. These options expire on June 17, 2035.

What are the vesting terms for AVTX director Kaplan's 2025 stock options?

The stock options vest 100% on the first anniversary of the grant date (June 17, 2026), subject to the director's continued service through the vesting date.

How long does Gilla Kaplan have to exercise the AVTX stock options granted in 2025?

The stock options have a 10-year term, with an expiration date of June 17, 2035.

What is the total value of AVTX stock options granted to Director Kaplan in June 2025?

Director Kaplan received 20,100 stock options with an exercise price of $4.47 per share. The Form 4 indicates these were granted at $0 cost to the director, though their potential value will depend on AVTX's future stock price performance.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/18/2025 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KAPLAN GILLA

(Last) (First) (Middle)

C/O AVALO THERAPEUTICS, INC.

1500 LIBERTY RIDGE DRIVE, SUITE 321

(Street)

WAYNE PA 19087

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Avalo Therapeutics, Inc. [ AVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$4.47	06/17/2025		A		20,100		(1)	06/17/2035	Common Stock	20,100	$0	20,100	D

Explanation of Responses:

1. The stock option vests 100% on the first anniversary of the date of grant, subject to the Eligible Director's continued service on such vesting date.

	/s/ Donald R. Reynolds, by Power of Attorney	06/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.